ReadR

ReadR

ReadR: Read and Share all content, headlines, news and trends results with Seefinish ReadR App.


Discover Content : Trends

Discover real-time trending topics, news headlines, twitter trends, google trends, hashtags, and content from different countries in the world.

Search Here

Navigation Tabs

Top Countries

Select Country:๐ŸŒ

Worldwide ๐ŸŒ | Nigeria ๐Ÿ‡ณ๐Ÿ‡ฌ | South Africa ๐Ÿ‡ฟ๐Ÿ‡ฆ | Kenya ๐Ÿ‡ฐ๐Ÿ‡ช |Brazil ๐Ÿ‡ง๐Ÿ‡ท| Canada ๐Ÿ‡จ๐Ÿ‡ฆ | United Kingdom ๐Ÿ‡ฌ๐Ÿ‡ง| United States ๐Ÿ‡บ๐Ÿ‡ธ



Headline : An isolated viral load test may generate false positive results for people using long-acting PrEP

Read more from the original article on here at www.nih.gov.





Tags : #isolated #viral #load #test #may #generate #false #positive #results #people #using #longacting #prep



No. of Paragraph 30

Analysis from large NIH study offers new insight on clinical utility of current U.S. testing algorithm.

A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably detect HIV in a multi-country study. In the study, a single positive viral load test was frequently found to be a false positive result. However, a second viral load test with a new blood sample was able to distinguish true positive results from false positive results for all participants whose initial viral load test was positive. The findings were presented at the 2024 International AIDS Conference (AIDS 2024) in Munich, Germany.

โ€œWe are still learning how to optimize the package of services that accompany long-acting PrEP, including HIV testing,โ€ said Jeanne Marrazzo, M.D., M.P.H., director of the National Institutes of Healthโ€™s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). โ€œThe viral load testing findings observed in this study illuminate performance gaps in the current U.S. HIV testing algorithm for injectable cabotegravir PrEP.โ€

Long-acting, injectable cabotegravir PrEP, known as CAB-LA, is a highly effective HIV prevention method, administered by intramuscular injection every two months. Routine HIV status monitoring is recommended for any form of PrEP to ensure that people can promptly be aware if they acquire HIV while taking PrEP drugs. In the United States, people taking oral PrEP can do this with point-of-care rapid tests and self-tests that detect HIV antibodies, or laboratory-based HIV testing. However, the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) recommend that people starting or taking CAB-LA PrEP receive a laboratory-based viral load test that detects HIV genetic material in the blood. This recommendation was made because CAB-LA can keep HIV antibodies at such low levels following acquisition that they might not be detected on an antibody-based test. To better inform the U.S. CAB-LA PrEP HIV testing algorithm, researchers examined the accuracy of viral load test results in an open-label extension of a large CAB-LA PrEP efficacy study.

Read more from the original article on here at www.nih.gov.


Related Headlines : An isolated viral load test may generate false positive results for people using long-acting PrEP (in Google.com):

Hello, below you have a "Web" tab to read more content and an "Image" tab to get related pictures

Example : Trends, Country, News, Jobs, Scholarships, Investment, Business, Politics, Adverts, Fashion, Events, Technology and more.